Systemic Immunomodulatory Therapy in Uveitis Related to Behçet’s Disease: A 10-year Profile
IMT effectively controls ocular inflammation in BD uveitis, significantly reducing relapse frequency. Azathioprine and cyclosporine remain first-line therapies. Discontinuing IMT after 4-6 years of sustained remission appears to be a safe strategy, particularly after 6 years.
Authors
- Mariana Almeida
- Ana Margarida Ferreira (ORCID: https://orcid.org/0009-0000-3592-2820)
- Luís Figueira (ORCID: https://orcid.org/0000-0002-4481-882X)
- Joana Araújo (ORCID: https://orcid.org/0000-0001-9649-3177)
Institutions
- Universidade do Porto (PT)
- Hospital de São João (PT)
Publication Details
- Journal
- Clinical ophthalmology
- Published
- 2025-07-01
- DOI
- https://doi.org/10.2147/opth.s524282
- Primary Topic
- Ocular Diseases and Behçet’s Syndrome
- Type
- article
- Field-Weighted Citation Impact
- 0.00